Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Abbott Laboratories, Inc.Dept. 0943, Bldg. AP6C 100 Abbott Park Road Abbott Park, IL 60064-6095

UEI: SLED_6FF90502D0FE63A0

Abbott Laboratories, Inc.Dept. 0943, Bldg. AP6C 100 Abbott Park Road Abbott Park, IL 60064-6095 is a federal contractor, registered under UEI SLED_6FF90502D0FE63A0. It has been awarded $875,000 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Gsa/fas Region 7 Acqusition Center.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_6FF90502D0FE63A0

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Gsa/fas Region 7 Acqusition Center$875.0K100%
Awards by NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$875.0K100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in Abbott Laboratories, Inc.Dept. 0943, Bldg. AP6C 100 Abbott Park Road Abbott Park, IL 60064-6095's top NAICS codes and agencies

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

about 14 hours ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is preparing to issue an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle, which supports military medical research and development services across four distinct market segments: medical research and development support, general research and development support, regulatory processes for human and animal research, and translational science services for moving innovations from laboratory to clinical practice. This on-ramp opportunity is exclusively set-aside for small businesses certified under the Small Business Administration’s 8(a) Program, with the aim of expanding the pool of qualified contractors while maintaining alignment with the existing unrestricted contract vehicle. The OMNIBUS IV IDIQ has a cumulative ceiling of $10 billion and has already generated over $600 million in task order awards across 51 task orders since its base period began in 2022, with the majority of activity occurring in fiscal years 2024 through 2026. Task orders are competitively awarded, including set-asides for 8(a) participants, and may be issued by various DoD entities including DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. The upcoming solicitation, expected to be posted on SAM.gov in late February 2026, follows a delay to align with the February 2026 implementation of the FAR Overhaul, which significantly impacts how small business status is handled under unrestricted IDIQ contracts. Under the new rules, contractors do not need to recertify their small business status at the task order level when bidding on 8(a)-set-aside work, as they may rely on their original IDIQ-level size and status representation—even if they have graduated from the 8(a) Program or grown beyond small business size thresholds. However, contractors must still recertify their status at the IDIQ level within 60 to 120 days prior to the end of the fifth contract year, in compliance with FAR 19.301-2(b)(1)(iii)(A). Proposals must be submitted via the PIEE Solicitation module using a SAM.gov-registered account, and while the initial pre-solicitation notice provides the framework and intent, detailed evaluation criteria, submission instructions, and contract clauses will be formally outlined in the forthcoming RFP. All awards under this on-ramp will be made to small business 8(a) participants, and the government anticipates issuing multiple new contracts
Defense Health Agency

POSTED

3 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Validation and Optimization of ONE-STEP Tagging in Human induced Pluripotent Stem Cells
Solicitation # NIH-NOI-PCA-NIA-01590
The National Institute on Aging (NIA), under the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), has issued a Notice of Intent to Sole Source for the validation and optimization of ONE-STEP tagging in human induced pluripotent stem cells (iPSCs). This acquisition aims to support the iPSC Neurodegenerative Disease Initiative (iNDI) and the Center of Alzheimer’s Disease and Related Dementias (CARD) by generating functionally engineered iPSC lines for research into Alzheimer’s disease and related dementias. The project involves high-activity guide identification, Bxb1 mRNA and cargo plasmid delivery optimization, and the generation of ADRD variant, MAPT 4R, and wild-type process-control clones. All deliverables must be repository-ready, meeting strict quality control standards including long-read sequencing, karyotype analysis, and SNP arrays to ensure scientific continuity and data integrity. The government intends to award this contract to The Jackson Laboratory, citing them as the only responsible source capable of meeting the requirements under FAR 6.302-1 and FAR 13.501(a). This determination is based on the laboratory's unique continuity with the existing iNDI program, established workflows for specific background lines, and proven success in large-scale CRISPR/Cas9 engineering. The total estimated contract value is 3,353,115.00 dollars, covering a base year from September 1, 2026, to August 31, 2027, and an option year extending to August 31, 2028. While this is a sole-source intent, the government will consider capability statements from other sources submitted by August 21, 2026, to determine if adequate competition exists.
National Institutes Of Health Olao

POSTED

3 days ago

DEADLINE

in 1 day
View Details